Clinical Trial Update: 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 8 weeks vs 12 weeks of elbasvir/grazoprevir in treatment-naïve chronic hepatitis C with mild fibrosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir/Grazoprevir (elbasvir/grazoprevir)

Snippet

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED